Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres

G. Longo, M. Federico, C. Pieresca, P. Avanzini, E. Iannitto, A. U. Di Prisco, L. Baldini, M. Brugiatelli, V. Clo', M. Bevini, V. Silingardi

Research output: Contribution to journalArticlepeer-review


Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD30+ were referred to one of the institutions participating in GISL (Gruppo Italiano per lo Studio dei Linformi). 16 patients were treated with ProMACE-CytaBOM, two with MACOP-B, one with CHOP and one with LSA2-L2. As of November 1990, all newly diagnosed patients were treated with MOPP/EBV/CAD hybrid. 27 (77%) cases of ALCL CD30+ and 8 (23%) cases of Hodgkin's-related (HR) lymphoma CD30+ were diagnosed. Extranodal disease was present in 22 cases (63%), and 8 patients (23%) had primary bone marrow involvement. Twenty-three complete remissions (CR) (66%), six partial remissions (PR) (17%) and six no remissions (NR) (17%) were achieved with induction therapy. Results achieved with ProMACE-CytaBOM and MOPP/EBV/CAD hybrid were comparable. The overall response rate (CR+PR) was 85% for patients with classic ALCL CD30+ and 87% for those with HR lymphoma CD30+. The 3 year estimated overall survival rate was 66% and the 3 year relapse free survival rate was 65% for the entire group. The only significant favourable prognostic factor was the achievement of CR with initial therapy. Our findings suggest that ALCL (CD30+/Ki-1+) has a clinical outcome similar to aggressive non-Hodgkin's lymphoma (NHL). The use of an anthracycline-containing regimen will provide a change of cure in approximately 65% of cases.

Original languageEnglish
Pages (from-to)1763-1767
Number of pages5
JournalEuropean Journal of Cancer
Issue number11
Publication statusPublished - 1995


  • aggressive chemotherapy
  • anaplastic large cell lymphoma (CD30+/Ki-1+)
  • CD30+ Hodgkin's-related lymphoma
  • non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology


Dive into the research topics of 'Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres'. Together they form a unique fingerprint.

Cite this